RTW backs Pyxis Oncology – RTW Venture Fund Limited has highlighted an announcement by Pyxis Oncology, Inc. On 30 March 2021 that company completed a $152 million Series B financing round, which was co-led by RTW Investments, LP.
The company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round together with other investment firms.
Pyxis is a privately held biotechnology company building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs – which are a combination of an antibody and a drug/toxin designed to kill cancer cells) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis will use the proceeds from the financing round to advance its differentiated portfolio of ADCs, a growing class of therapies that deliver highly potent targeted treatments directly to cancer cells, including PYX-201 and PYX-203 programmes.
Gotham Makker, M.D., head of strategic investments at the investment manager, will join Pyxis’ board of directors.
PXY201, PYX202 and PYX203 are in preclinical development. PYX201 targets an antigen that is overexpressed in several tumour types, PYX202 targets a tumour cell surface antigen that is expressed in a range of solid tumours and PYX203 targets an antigen expressed in haematologic malignancies